MeiraGTx Holdings PLC
MGTX7.815USD
+0.165+2.16%
시장 운영 시간 （ET）시세는 15분 지연됩니다
620.66M시가총액
손실P/E TTM
자세한 내용은 MeiraGTx Holdings PLC 회사
MeiraGTx Holdings PLC is a vertically integrated, clinical-stage gene therapy company. The Company is focused on three distinct areas of unmet medical need: ocular diseases, including inherited retinal diseases (IRDs), as well as large degenerative ocular diseases, severe forms of xerostomia and neurodegenerative diseases. Its product pipeline includes botaretigene sparoparvovec or bota-vec, for the treatment of X-linked retinitis pigmentosa related to mutations in the retinitis pigmentosa GTPase regulator gene or XLRP-RPGR; AAV-hAQP1 for the treatment of radiation-induced Grade 2/3 Xerostomia; AAV-hAQP1 for the treatment of Sjogren’s Syndrome; AAV-GAD for the treatment of Parkinson’s Disease; AAV-RPE65 for the treatment of RPE65-asociated retinal dystrophy; AAV-CNGB3 and AAV-CNGA3 for the treatment of achromatopsia; AAV-AIPL1 for the treatment of LCA4, and AAV-RDH12 for the treatment of RDH12 mutation-associated retinal dystrophy.
회사 정보
종목 코드 MGTX
회사 이름MeiraGTx Holdings PLC
상장일Jun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
직원 수381
유형Ordinary Share
회계 연도 종료Jun 08
주소450 East 29Th Street
도시NEW YORK
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호10016
전화16468607985
웹사이트https://meiragtx.com/
종목 코드 MGTX
상장일Jun 08, 2018
CEODr. Alexandria Forbes, Ph.D.
회사 임원
이름
이름/직위
직위
주식 보유
변동
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
Mr. Robert J. Wollin, J.D.
Mr. Robert J. Wollin, J.D.
General Counsel, Secretary
General Counsel, Secretary
31.15K
+50.01%
Ms. Ellen Hukkelhoven, Ph.D.
Ms. Ellen Hukkelhoven, Ph.D.
Independent Director
Independent Director
--
--
Ms. Nicole Seligman
Ms. Nicole Seligman
Independent Director
Independent Director
--
--
Mr. Neil F. J. (Lord) Mendoza
Mr. Neil F. J. (Lord) Mendoza
Independent Director
Independent Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Dr. Alexandria Forbes, Ph.D.
Dr. Alexandria Forbes, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
1.36M
-3.37%
Mr. Richard Giroux
Mr. Richard Giroux
Chief Financial Officer, Chief Operating Officer
Chief Financial Officer, Chief Operating Officer
943.65K
-2.48%
Dr. Stuart Naylor, Ph.D.
Dr. Stuart Naylor, Ph.D.
Chief Development Officer
Chief Development Officer
623.29K
--
Mr. Thomas E. Shenk, Ph.D.
Mr. Thomas E. Shenk, Ph.D.
Independent Director
Independent Director
157.48K
--
Mr. Robert K. Zeldin, M.D.
Mr. Robert K. Zeldin, M.D.
Chief Medical Officer
Chief Medical Officer
136.52K
+7.14%
Dr. Keith R. Harris, Ph.D.
Dr. Keith R. Harris, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
125.00K
+150.00%
수익 분석
데이터 없음
데이터 없음
사업별
지역별
데이터 없음
주식 보유 통계
마지막 업데이트: Wed, Jun 4
마지막 업데이트: Wed, Jun 4
주주
주주 유형
주주
주주
비율
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
주주
주주
비율
Perceptive Advisors LLC
15.65%
Sanofi SA
15.18%
Johnson & Johnson Innovation-JJDC, Inc.
8.26%
Adage Capital Management, L.P.
7.01%
Prosight Capital
4.59%
Other
49.30%
주주 유형
주주
비율
Hedge Fund
21.86%
Corporation
20.11%
Private Equity
15.65%
Venture Capital
8.26%
Investment Advisor
7.44%
Investment Advisor/Hedge Fund
5.60%
Individual Investor
4.27%
Research Firm
0.89%
Pension Fund
0.08%
Other
15.83%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
230
67.81M
84.38%
+4.14M
2025Q1
245
80.15M
99.86%
+3.86M
2024Q4
246
77.41M
99.87%
+22.10M
2024Q3
250
64.74M
84.14%
+9.72M
2024Q2
251
52.33M
80.03%
+4.22M
2024Q1
254
51.24M
78.85%
+2.58M
2023Q4
253
50.76M
80.27%
+3.66M
2023Q3
255
41.86M
71.40%
-5.70M
2023Q2
256
41.99M
71.79%
-2.93M
2023Q1
256
32.89M
67.58%
-5.40M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Perceptive Advisors LLC
12.58M
15.65%
--
--
Mar 31, 2025
Sanofi SA
12.20M
15.18%
--
--
Mar 31, 2025
Johnson & Johnson Innovation-JJDC, Inc.
6.64M
8.26%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
5.63M
7.01%
+600.00K
+11.92%
Mar 31, 2025
Prosight Capital
3.69M
4.59%
-699.29K
-15.93%
Mar 31, 2025
Adena Estate Inc.
3.27M
4.06%
+3.27M
--
Dec 31, 2023
BlackRock Institutional Trust Company, N.A.
2.73M
3.39%
+87.69K
+3.32%
Mar 31, 2025
683 Capital Management LLC
2.58M
3.2%
+160.00K
+6.63%
Mar 31, 2025
Rubric Capital Management LP
1.78M
2.21%
+1.78M
--
Mar 31, 2025
Forbes (Alexandria)
1.41M
1.75%
-47.50K
-3.26%
Apr 08, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.06%
Invesco Nasdaq Biotechnology ETF
0.06%
Goldman Sachs Innovate Equity ETF
0.04%
iShares Biotechnology ETF
0.04%
SPDR S&P International Small Cap ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
iShares Russell 2000 Value ETF
0.01%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0.01%
더 보기
iShares Micro-Cap ETF
비율0.06%
ProShares Ultra Nasdaq Biotechnology
비율0.06%
Invesco Nasdaq Biotechnology ETF
비율0.06%
Goldman Sachs Innovate Equity ETF
비율0.04%
iShares Biotechnology ETF
비율0.04%
SPDR S&P International Small Cap ETF
비율0.02%
Invesco RAFI US 1500 Small-Mid ETF
비율0.01%
iShares Russell 2000 Value ETF
비율0.01%
iShares Russell 2000 Growth ETF
비율0.01%
Global X Russell 2000 ETF
비율0.01%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
